<DOC>
	<DOCNO>NCT02549092</DOCNO>
	<brief_summary>The primary objective study examine effect Levodopa-Carbidopa Intestinal Gel ( LCIG ) relative OMT non-motor symptom associate Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>A Study Examine Effect Levodopa-Carbidopa Intestinal Gel ( LCIG ) Therapy Relative That Optimized Medical Treatment ( OMT ) Non-motor Symptoms ( NMS ) Associated With Advanced Parkinson 's Disease ( PD )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Participant ( ) must diagnosis idiopathic Parkinson 's disease accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria . 2 . Participant ( ) demonstrate persistent motor fluctuation spite individually optimize treatment . 3 . The participant 's Parkinson 's disease levodoparesponsive . 4 . Participant ( ) optimize treatment available antiPD medication motor symptom judge inadequately control optimize treatment . Optimized treatment define maximum therapeutic effect obtain pharmacological antiparkinsonian therapy improvement expect regardless additional manipulation levodopa and/or antiparkinsonian medication . This base Investigator 's clinical judgment . 5 . Male female participant ( ) must least 30 year age . 1 . Participant 's PD diagnosis unclear suspicion subject parkinsonian syndrome secondary parkinsonism ( e.g . cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , parkinsonplus syndrome ( e.g . Multiple System Atrophy , Progressive supranuclear Palsy , Diffuse Lewy Body disease ) neurodegenerative disease might mimic symptom PD . 2 . Participant ( ) undergone neurosurgery treatment Parkinson 's disease . 3 . Known hypersensitivity levodopa , carbidopa radiopaque material . 4 . Participant ( ) contraindication levodopa ( e.g . narrow angle glaucoma , malignant melanoma ) . 5 . Participant ( ) experience clinically significant sleep attack clinically significant impulsive behavior ( e.g . pathological gambling , hypersexuality ) point three month prior Screening evaluation judge Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>carbidopa</keyword>
	<keyword>efficacy</keyword>
	<keyword>Advanced Parkinson 's Disease</keyword>
	<keyword>Parkinson 's Disease Sleep Scale PDSS-2</keyword>
	<keyword>levodopa-carbidopa intestinal gel</keyword>
	<keyword>Non-Motor Symptom Scale NMSS</keyword>
	<keyword>levodopa</keyword>
</DOC>